Abstract
Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics.This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.
| Original language | English |
|---|---|
| Pages (from-to) | 189-192 |
| Number of pages | 4 |
| Journal | Oncologist |
| Volume | 28 |
| Issue number | 3 |
| DOIs | |
| State | Published - 17 Mar 2023 |
Keywords
- Analgesics, Opioid/therapeutic use
- Cancer Pain/drug therapy
- Catechol O-Methyltransferase/genetics
- Cytochrome P-450 CYP2D6/genetics
- Genotype
- Humans
- Morphine/therapeutic use
- Neoplasms/drug therapy
- Oxycodone/therapeutic use
- Pain Management
- Pharmacogenetics
Fingerprint
Dive into the research topics of 'Evidence Regarding Pharmacogenetics in Pain Management and Cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver